** Shares of ASX-listed shares of ResMed slump as much as 6.3% to A$27.050, set to see their worst day since Aug 7, 2023 - if losses hold
** Eli Lilly said on Wednesday that its weight-loss drug helped reduce episodes of irregular breathing associated with sleep apnea - a common sleep-related disorder
** RMD makes devices that are used to treat sleep apnea, thereby stoking competition concerns
** Shares hit lowest since March 4
** ASX-listed shares emerge as top loser on benchmark
** Stock has risen 13.5% this year as of last close
(Reporting by Archishma Iyer)
((Archishma.Iyer@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments